A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP)

BACKGROUND: In preclinical models, recombinant human relaxin-2 (serelaxin) had anti-fibrotic effects and ameliorated portal hypertension (PH). A small exploratory study in patients with cirrhosis also suggested that serelaxin could reduce portal pressure. METHODS: In a phase 2, double-blind, randomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gifford, Fiona J., Dunne, Philip D. J., Weir, Graeme, Ireland, Hamish, Graham, Catriona, Tuck, Sharon, Hayes, Peter C., Fallowfield, Jonathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066808/
https://www.ncbi.nlm.nih.gov/pubmed/32164767
http://dx.doi.org/10.1186/s13063-020-4203-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066808/
https://www.ncbi.nlm.nih.gov/pubmed/32164767
http://dx.doi.org/10.1186/s13063-020-4203-9

Ejemplares similares